Targeting cross-presentation as a route to improve the efficiency of peptide-based cancer vaccines

Cross-presenting dendritic cells (DC) offer an attractive target for vaccination due to their unique ability to process exogenous antigens for presentation on MHC class I molecules. Recent reports have established that these DC express unique surface receptors and play a critical role in the initiation of anti-tumor immunity, opening the way for the development of vaccination strategies specifically targeting these cells.

Citation:
Wylie B, Ong F, Belhoul-Fakir H, Priebatsch K, ……. Waithmain J. Targeting cross-presentation as a route to improve the efficiency of peptide-based cancer vaccines. Cancers. 2021;13(24).

Keywords:
Cancer vaccine; Cell penetrating peptide; Cross-presentation
Dendritic cell; Immunotherapy; Melanoma; Peptide vaccine

Abstract:
Cross-presenting dendritic cells (DC) offer an attractive target for vaccination due to their unique ability to process exogenous antigens for presentation on MHC class I molecules. Recent reports have established that these DC express unique surface receptors and play a critical role in the initiation of anti-tumor immunity, opening the way for the development of vaccination strategies specifically targeting these cells.